Marchex (MCHX) Announces Regular Quarterly Dividend for Common Stock

Marchex, Inc. (NASDAQ:MCHX) today announced that the company’s Board of Directors has declared a regular quarterly dividend in the amount of $0.02 per share on its common stock. Marchex will pay these dividends on August 15, 2012 to the holders of record as of the close of business on August 3, 2012. As of July 13, 2012, 9,570,382 shares of Class A common stock and 28,197,745 shares of Class B common stock are outstanding.

Marchex commenced the payment of a regular quarterly cash dividend on its common stock on February 15, 2007. The company intends to pay a regular quarterly dividend on its common stock for the foreseeable future at the discretion of the Board of Directors depending on available cash, anticipated cash needs, overall financial condition, future prospects for earnings and cash flows as well as other relevant factors.

About Marchex

Marchex, Inc. is a leading mobile and online advertising company that drives millions of consumers to connect with businesses over the phone, delivers the most quality phone calls in the industry, and provides in-depth analysis of those phone calls.

Marchex supports its customers through a unique technology platform that has three primary components: (1) Call Analytics, which powers all of our advertising solutions, and allows partners to leverage data and insights that accurately measure the performance of mobile, online and offline call advertising; (2) Digital Call Marketplace, which connects hundreds of millions of consumer calls to our advertisers annually from a range of mobile and online sources on a Pay For Call basis; and (3) Local Leads, a white-labeled, full-service digital advertising solution for small business resellers that drives quality phone calls and other leads to their small business advertisers.

Marchex is based in Seattle. To learn more, please visit marchex.com/products.

Forward-Looking Statements:

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenues, acquisitions, projected costs, prospects, plans and objectives of management are forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. There are a number of important factors that could cause Marchex’s actual results to differ materially from those indicated by such forward-looking statements which are described in the “Risk Factors” section of our most recent periodic report and registration statement filed with the SEC. All of the information provided in this release is as of July 13, 2012 and Marchex undertakes no duty to update the information provided herein.

Misonix (MSON) And Soelim Create New Distribution Alliance For South Korea

Banro (BAA) Provides Update

TORONTO, ONTARIO — (Marketwire) — 07/13/12 — Banro Corporation (“Banro” or the “Company”) (NYSE MKT:BAA)(NYSE Amex:BAA)(TSX:BAA) wishes to provide a brief comment on its operations in respect of disturbances in the NE DRC which are being reported by various media.

While the Company is aware of activities along the northeast border of the DRC, Banro’s Twangiza gold mine continues to operate unaffected by this, and the Company is carrying on with its planned activities at its other projects at Namoya, Kamituga and Lugushwa. Banro has a number of supply route options for its Twangiza operation, including those through Burundi and/or Tanzania – routes which have been established to service the logistical requirements of the Namoya development project and these continue to operate seamlessly. Development at Banro’s second gold mine, Namoya, is progressing as are adjustments to the processing plant at Twangiza (see Banro press release dated June 21, 2012) which are on schedule.

The international community is closely monitoring NE DRC activities and is being proactive in dealing with this isolated pocket of disturbance. The Company is confident that this current situation, which has attracted the attention of the media, will be resolved through such efforts, as has been the case with similar situations in the past.

Banro Corporation is a Canadian gold mining company focused on production from the Twangiza oxide mine and development of three additional major, wholly-owned gold projects, each with mining licenses, along the 210 kilometre long Twangiza-Namoya gold belt in the South Kivu and Maniema provinces of the Democratic Republic of the Congo. Led by a proven management team with extensive gold and African experience, Banro’s plans include the construction of its second gold mine at Namoya, at the south end of this gold belt, as well as the development of two other projects, Lugushwa and Kamituga, in the central portion of the belt. The initial focus of the Company is on oxides, which attract a lower technical and financial risk to the Company and will also maximize cash flows in order to develop the belt with minimal further dilution to shareholders. All business activities are followed in a socially and environmentally responsible manner.

For further information, please visit our website at www.banro.com.

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding estimates and/or assumptions in respect of gold production, cash flow and costs, estimated project economics and the Company’s development plans and objectives) are forward-looking statements. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Company. Factors that could cause actual results or events to differ materially from current expectations include, among other things: uncertainty of estimates of capital and operating costs, production estimates and estimated economic return; the possibility that actual circumstances will differ from the estimates and assumptions used in the economic studies of the Company’s projects; failure to establish estimated mineral resources or mineral reserves; fluctuations in gold prices and currency exchange rates; inflation; gold recoveries being less than those indicated by the metallurgical testwork carried out to date (there can be no assurance that gold recoveries in small scale laboratory tests will be duplicated in large tests under on-site conditions or during production); uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; political developments in the Democratic Republic of the Congo; lack of infrastructure; failure to procure or maintain, or delays in procuring or maintaining, permits and approvals; lack of availability at a reasonable cost or at all, of plants, equipment or labour; inability to attract and retain key management and personnel; changes to regulations affecting the Company’s activities; the uncertainties involved in interpreting drilling results and other geological data; and the other risks disclosed under the heading “Risk Factors” and elsewhere in the Company’s annual information form dated March 26, 2012 filed on SEDAR at www.sedar.com and EDGAR at www.sec.gov.

Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.

Contacts:
Banro Corporation
Simon Village
CEO & President
+44 1959 575 039

Banro Corporation
Arnold T. Kondrat
Executive Vice-President
+1 (416) 366-2221

Banro Corporation
Naomi Nemeth
Investor Relations
+1 (416) 366-9189 or +1-800-714-7938, Ext 2802
info@banro.com

CallidusCloud (CALD) Selects Badgeville to Power MySalesGame

PLEASANTON, CA — (Marketwire) — 07/13/12 — Callidus Software Inc. (NASDAQ: CALD), announced today its partnership with Badgeville©, The Behavior Platform™ and leader in enterprise gamification, to deliver MySalesGame, CallidusCloud’s™ new sales gamification solution to enhance performance and productivity across the entire sales ecosystem.

CallidusCloud’s MySalesGame is a social sales performance management platform that drives selling behavior by publishing peer performance on key sales objectives in real time and providing social currency, redeemable for rewards. MySalesGame uses gamification techniques to revolutionize the way companies measure, motivate, train, coach and enable their sales force to take sales performance to the next level.

“Gamification is a way of harnessing people’s natural competitive instincts and applying them to the sales process for improved engagement and performance,” said Giles House, VP Marketing Communications and Products, CallidusCloud. “Badgeville’s Behavior Platform enables us to deliver MySalesGame in rapid time across our product and partner ecosystem, including marketing automation, sales performance management and learning management, so that companies can start to enjoy the benefits of improved sales engagement.”

Badgeville enables enterprises to incentivize high-value behavior across internal and external audiences. The company, which recently raised $25M in Series C funding, is a fast-growing SaaS startup, with over 175 customers worldwide in under two years of business. Badgeville’s unique technology platform enables businesses to easily measure and influence behavior across their entire digital ecosystem of websites and applications.

“CallidusCloud selecting Badgeville to power MySalesGame signifies The Behavior Platform’s clear dominance in gamification for serious enterprise businesses,” said Kevin Akeroyd, SVP, Badgeville. “The innovative work the CallidusCloud team is doing to deeply embed gamification across all of their sales management applications is unprecedented. It offers a glimpse into the future of gamification for business, where incentives and rewards are ingrained in our everyday professional experiences.”

MySalesGame is delivered as part of CallidusCloud’s sales and marketing suite, a SaaS suite that is designed to help businesses drive enterprise engagement, sales performance management and sales effectiveness throughout the sales cycle with award-winning, multi-tenant cloud software. CallidusCloud offers the following SaaS and mobile solutions: candidate assessment tests for hiring, video interviews, marketing automation, quotes and proposals, sales enablement, sales coaching, sales commission management, learning management and content authoring, underpinned by analytics and enterprise gamification.

Follow our Sales Pulse blog, join us on LinkedIn and Facebook or follow us on Twitter for real-time updates.

About Badgeville
Badgeville (www.badgeville.com), The Behavior Platform, is the leading provider of gamification and social engagement solutions for world-class businesses, enabling companies in virtually every industry to influence and measure user behavior. Companies and organizations from across the globe use Badgeville’s award-winning SaaS solution to increase customer loyalty, user engagement and employee performance. With 175 customers, Badgeville brings Game Mechanics, Reputation Mechanics, and Social Mechanics to world-class companies including Deloitte, EMC, Universal Music, Samsung, CA Technologies, Dell, Bell Media, NBC, The Active Network, and Recyclebank. Founded in 2010, Badgeville is based in Menlo Park, California and has offices in New York and Europe. Follow @Badgeville to learn more.

About Callidus Software
Callidus Software Inc. (NASDAQ: CALD) is the market and technology leader in sales effectiveness and cloud computing. Our customers gain a competitive advantage by maximizing sales cost efficiencies and driving improvements in sales effectiveness. CallidusCloud’s award-winning multi-tenant SaaS applications set the standard for performance management of a company’s sales force and channel partners. Over 2.5 million users rely on our solutions to power their performance. For more information, please visit www.calliduscloud.com.

©2012. Callidus Software Inc. All rights reserved. Callidus, Callidus Software, the Callidus Software logo, CallidusCloud, the CallidusCloud logo, TrueComp Manager, ActekSoft, ACom3, ForceLogix, Salesforce Assessments, iCentera, Webcom, Litmos, the Litmos logo, LeadFormix, Rapid Intake and 6FigureJobs are trademarks, service marks, or registered trademarks of Callidus Software Inc. and its affiliates in the United States and other countries. All other brand, service or product names are trademarks or registered trademarks of their respective companies or owners.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Press Contact:
Giles House
CallidusCloud
925-251-2200

Document Security Systems’ (DSS) Motions Hearing in Coupons.com Case Rescheduled

ROCHESTER, N.Y., July 13, 2012 /PRNewswire/ — Document Security Systems, Inc. (NYSE MKT: DSS; “DSS”), a leading developer and integrator of cloud computing data security, Radio Frequency Identification (“RFID”) systems and security printing technologies which prevent counterfeiting, product diversion and brand fraud, announced today it has been informed by the United States District Court for the Western District of New York that the previously scheduled motions hearing in connection with the company’s pending litigation matter involving Coupons.com  has been moved up from October 9th, 2012 to August 16th, 2012.

In October 2011, DSS filed a law suit against Coupons.com alleging that Coupons.com misappropriated DSS trade secrets and breached confidentiality agreements with DSS.  The suit involves DSS’s proprietary digital copy protection technology; DSS contends that this technology has been utilized by Coupons.com on billions of internet generated coupons.

About DSS (Document Security Systems, Inc.):

DSS provides counterfeit prevention, RFID tracking and comprehensive brand and digital information protection solutions to corporations, governments, and financial institutions around the world.  DSS develops and manufactures secure printed products such as labels, packaging, ID Cards, RFID Cards and tags and documents using their AuthentiGuard line of patented optical deterrent and authentication technologies. The company also provides cloud computing security services, provides disaster recovery backup, writes custom software solutions, and integrates track and trace technologies.

For more information on DSS and its subsidiaries, please visit DSSsecure.com.

DSS is comprised of four operating units:

DSS Plastics Group – Custom RFID and Plastic ID Card Solutions (Brisbane, CA) PH: 1-415-585-9600

DSS Packaging Group – Commercial and Secure Packaging Manufacturing (Victor, NY) PH:  585-924-8460

DSS Printing Group – Commercial and Security Printing Manufacturing (Rochester, NY) PH: 585-341-3100

DSS Digital Group – Cloud Computing Services and Secure Digital/Internet Documents (Rochester, NY) PH: 585-746-6958

For more information on DSS and its subsidiaries, please visit DSSsecure.com.

Follow Document Security Systems, Inc. on LinkedIn, Facebook, Twitter and WordPress

For more information:
Investor Relations:
CenturyIR.com
Phone:  212-776-1030

Safe Harbor Statement

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding expectations for future financial performance, potential sales from new and existing customers, expected benefits from the Company’s cost cutting efforts and/or statements preceded by, followed by or that include the words “believes,” “could,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “projects,” “seeks,” or similar expressions, all of which involve uncertainty and risk. Many of these risks and uncertainties are discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 filed with the Securities and Exchange Commission (the “SEC”), and in any subsequent reports filed with the SEC, all of which are available at the SEC’s website at www.sec.gov. It is possible the company’s future financial performance may differ from expectations due to a variety of factors including, but not limited to, the risks referred to above, and changes in economic and business conditions in the world, increased competitive activity, achieving sales levels to fulfill revenue expectations, consolidation among its competitors and customers, technology advancements, unexpected costs and charges, adequate funding for plans, changes in interest and foreign exchange rates, regulatory and other approvals and failure to implement all plans, for whatever reason. It is not possible to foresee or identify all such factors. Any forward-looking statements in this report are based on current conditions; expected future developments and other factors it believes are appropriate in the circumstances. Prospective investors are cautioned that such statements are not a guarantee of future performance and actual results or developments may differ materially from those projected. The company makes no commitment to update any forward-looking statement included herein, or disclose any facts, events or circumstances that may affect the accuracy of any forward-looking statement.

Misonix (MSON) Adds Industry Veteran To Management Team

FARMINGDALE, N.Y., July 12, 2012 /PRNewswire/ — Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, has announced the addition of industry veteran, Christopher A. DeNicola, to its sales management team.  Mr. DeNicola joined the Company on July 1, 2012, as Senior Director of Sales – North America for its neurosurgery, spine surgery and orthopedic surgery products.  Products in this category are the SonaStar® Ultrasonic Surgical Aspiration System and the BoneScalpel™ Ultrasonic Bone Cutting System.

Mr. DeNicola, who is degreed in Management, has almost 20 years of successful sales management experience in Orthopedic Surgery, Neurosurgery and Podiatric Surgery, with a heavy concentration in Spine Surgery.  He has worked with direct, distributor and hybrid sales organizations.  Previous employers included EBI (a Biomet Company), Small Bone Innovations and Scient’x USA.  The Company expects that Mr. DeNicola’s presence will add measurably to the rapid expansion of its Neuro/Orthopedic sales organization.

The SonaStar is used by neurosurgeons and general surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels.  OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of safely making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.  Use of this product is being rapidly accepted by spine and skull-based surgeons on a worldwide basis.

“We are very pleased to add a sales executive of Chris DeNicola’s experience and stature to our growing domestic sales organization,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.  “His knowledge of distributors, combined with his established relationships with physician thought leaders in our target markets, should prove to be quite valuable in rapidly expanding our domestic market presence.”

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.

EnteroMedics (ETRM) Reports Exercise of 1,653,635 Common Stock Warrants

ST. PAUL, MN — (Marketwire) — 07/12/12 — EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders today announced that it has received $3.6 million from the exercise of 1,653,635 warrants through 2012 to date. The warrants that were exercised were issued by the Company in its December 2010 and September 2011 public offerings and had exercise prices of $2.19 per share and $1.90 per share, respectively. The Company intends to use the proceeds from the warrant exercises for general corporate purposes. As of July 11, 2012, 17,067,146 warrants remain outstanding and exercisable from the aforementioned offerings with exercise prices ranging from $2.19 to $1.90 per share.

“We appreciate this investment from our existing stockholders, which continues to support our ability to achieve our milestones and our ongoing strategy,” said President and Chief Executive Officer, Mark B. Knudson, PhD.

About EnteroMedics Inc.

EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. EnteroMedics’ proprietary technology, VBLOC® vagal blocking therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. VBLOC allows people with obesity to take a positive path towards weight loss, addressing the lifelong challenge of obesity and its comorbidities without sacrificing wellbeing or comfort. EnteroMedics has received CE Mark and is listed on the Australian Register of Therapeutic Goods.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our lack of commercial regulatory approval for our Maestro® System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; our preliminary findings from our EMPOWER™ pivotal trial; our ability to comply with the Nasdaq continued listing requirements; our ability to commercialize our Maestro System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our Maestro System; physician adoption of our Maestro System and VBLOC® vagal blocking therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission, particularly those factors identified as “risk factors” in the annual report on Form 10-K filed March 15, 2012. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Caution – Investigational device. Limited by Federal (United States) law to investigational use. EnteroMedics has received CE Mark and is listed on the Australian Register of Therapeutic Goods.

The implantation procedure and usage of the Maestro® System carry some risks, such as the risks generally associated with laparoscopic procedures and those related to treatment as described in the ReCharge clinical trial informed consent.

Contact:
EnteroMedics Inc.
Greg S. Lea
(651) 789-2860

Autobytel (ABTL) Announces Effectiveness of 1-for-5 Reverse Stock Split

Autobytel Inc. (Nasdaq: ABTL), a leading provider of online consumer purchase requests and marketing resources for the automotive industry, today announced that the previously announced 1-for-5 reverse split of the Company’s common stock, $0.001 par value per share, took effect after the close of trading on the NASDAQ Capital Market on July 11, 2012. The Company’s common stock will begin trading on a reverse stock split-adjusted basis on the NASDAQ Capital Market as of the opening of trading on July 12, 2012. The common stock will continue to be reported on the NASDAQ Capital Market under the symbol “ABTL,” with 05275N205 as its new CUSIP number.

Upon the effectiveness of the reverse stock split, each five shares of the Company’s issued and outstanding common stock automatically combined and converted into one issued and outstanding share of common stock, par value $0.001 per share. The reverse stock split affected all issued and outstanding shares of the Company’s common stock, as well as common stock underlying stock options, warrants and convertible notes outstanding immediately prior to the effectiveness of the reverse stock split. The reverse stock split reduced the number of outstanding shares of the Company’s common stock outstanding prior to the reverse stock split from approximately 44.256 million to approximately 8.851 million. The number of authorized shares of the Company’s common stock was not affected by the reverse stock split.

No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a fractional share of the Company’s common stock will receive a cash payment in lieu of such fractional share based on the average per share closing price of the common stock on the NASDAQ Capital Market for the five trading days prior to the effective date of the reverse stock split, which is $0.78.

Stockholders with shares held in book-entry form or through a bank, broker or other nominee are not required to take any action and will see the impact of the reverse stock split reflected in their accounts after July 12, 2012. Beneficial holders may contact their bank, broker or nominee for more information. Stockholders with shares held in certificate form are required to exchange their stock certificates for book-entry shares representing the shares of common stock resulting from the reverse stock split. Shortly after July 12, 2012, registered holders who hold stock in certificate form will receive a Letter of Transmittal and instructions for exchanging their certificates from the Company’s exchange agent, Computershare Trust Company, N.A.

Additional information about the reverse stock split can be found in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 27, 2012, a copy of which is available at www.sec.gov or at www.autobytel.com under the SEC Filings tab located on the Investor Relations page.

About Autobytel Inc.
Autobytel Inc., an online leader offering consumer purchase requests and marketing resources to car dealers and manufacturers and providing consumers with the information they need to purchase new and used cars, pioneered the automotive Internet when it launched its flagship website, autobytel.com, in 1995. Autobytel continues to offer innovative products and services to help consumers buy, and auto dealers and manufacturers sell, more used and new cars. Autobytel has helped tens of millions of automotive consumers research vehicles; connected thousands of dealers nationwide with motivated car buyers; and helped every major automaker market its brand online. Through its flagship website, its network of automotive sites and respected online affiliates, Autobytel continues its dedication to innovating the industry’s highest quality Internet programs to provide consumers with a comprehensive and positive automotive research and purchasing experience, and auto dealers, dealer groups and auto manufacturers with some of the industry’s most productive and cost-effective customer referral and marketing programs. Investors and other interested parties can receive Autobytel news releases and invitations to special events by accessing our online signup form at http://investor.autobytel.com/alerts.cfm

Forward-Looking Statements Disclaimer
The statements contained in this press release that are not historical facts are forward-looking statements under the federal securities laws. These forward-looking statements by their nature address matters that are uncertain. Investors are strongly encouraged to review the company’s Annual Report on Form 10-K for the year ended December 31, 2011, and other filings with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect the business, operating results or financial condition of Autobytel and the market price of the company’s stock. In addition, current year financial information could be subject to change as a result of subsequent events or the finalization of the company’s financial statement close which culminates with the filing of the company’s Annual Report on Form 10-K for the current year.

AVI BioPharma (AVII) Announces Name/Ticker Change to Sarepta Therapeutics (SRPT)

BOTHELL, WA — (Marketwire) — 07/12/12 — AVI BioPharma, Inc. (NASDAQ: AVII) today announced that it has changed its name to Sarepta Therapeutics, Inc. (“the Company”) and has effected a one-for-six reverse stock split. The name change and reverse stock split were approved by the Company’s shareholders at its Annual Meeting of Shareholders held on July 10, 2012, and the specific one-for-six ratio was agreed upon and approved by the Company’s Board of Directors. Sarepta is focused on the development of first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company’s development programs include its lead therapeutic candidate, eteplirsen, for the treatment of Duchenne muscular dystrophy (DMD), as well as potential treatments for the lethal hemorrhagic fever viruses Ebola and Marburg.

The Company’s common stock will trade on a split-adjusted basis on The NASDAQ Global Market when the market opens today, July 12, 2012, and will trade under the new ticker symbol (NASDAQ: SRPT).

“The introduction of our new brand, under the name of Sarepta Therapeutics, is part of a broader revitalization that represents an important and exciting new phase for our company,” said Chris Garabedian, president and CEO of Sarepta Therapeutics. “Our rapidly advancing clinical programs have positioned us on the threshold of realizing the potential of our innovative and unique RNA-based technology. We are committed to building a leading, independent biotech company, dedicated to translating our RNA-based science into transformational therapies for patients impacted by serious and life-threatening diseases.”

About the Reverse Stock Split

Upon enactment of the reverse stock split, every six shares of the Company’s issued and outstanding common stock will be automatically converted into one issued and outstanding share of common stock, without any change in par value per share. The reverse stock split will affect all issued and outstanding shares of the Company’s common stock, as well as common stock underlying stock options, warrants and other common stock based equity grants outstanding immediately prior to the effectiveness of the reverse stock split. No fractional shares will be issued in connection with the reverse stock split, but Sarepta will purchase all fractional shares that otherwise would have been issued as a result of the transaction. Shareholders who would otherwise hold a fractional share of Sarepta common stock will receive a cash payment in lieu of the fractional share based on the closing price of the Company’s common stock as quoted on The NASDAQ Global Market for the five trading days immediately preceding the effective date of the reverse stock split. Additional information about the reverse stock split and the impact it will have on the Company’s stock is set forth in the Company’s proxy statement filed with the U.S. Securities and Exchange Commission on June 13, 2012. The reverse stock split will reduce the number of shares outstanding from approximately 135.7 million to approximately 22.6 million. Concurrently, Sarepta will reduce its authorized number of common shares to 50.0 million. As a result of the reverse stock split, the Company expects to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Global Market.

Computershare is acting as Sarepta’s transfer agent for the reverse stock split. Shareholders holding certificated shares or shares through a brokerage account will have their shares automatically adjusted to reflect the reverse stock split as of the effective date. The issuance of new stock certificates will not be required; however, shareholders may obtain a new certificate from Computershare if desired.

“The completion of a reverse stock split is an important step to strengthen our financial base and regain compliance with NASDAQ so that we are in a stronger position to support and advance our technology platform and our lead clinical candidate, eteplirsen, for the treatment of Duchenne muscular dystrophy,” said Mr. Garabedian.

About Sarepta Therapeutics

Sarepta Therapeutics — formerly AVI BioPharma — is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company’s diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world’s most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com.

Forward Looking Statements

This press release contains forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company’s expectations or beliefs, including any such statement about the effects of the reverse stock split, is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing therapeutics, including the adequacy of the Company’s capital to support the Company’s operations, the Company’s ability to raise additional funds and the potential terms of such potential financing, the Company’s ability to maintain the listing of its common stock on The NASDAQ Global Market and the timing and prospects for the commercialization of eteplirsen and the Company’s other therapeutics currently in development. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company’s business are described in additional detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, as amended, and the Company’s other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

AVI Media and Investor Contact:
Erin Cox
425.354.5140

Hemispherx Biopharma (HEB) and the FDA Reach Agreement

Targeted Filing Date in 3rd Quarter 2012

PHILADELPHIA, July 11, 2012 (GLOBE NEWSWIRE) — Hemispherx Biopharma, Inc. (NYSE:HEB) (the “Company” or “Hemispherx”) recently met with representatives of the U.S. Food and Drug Administration (the “FDA”). At that meeting, the FDA agreed to accept, for review, new analyses of data from Hemispherx’s AMP-516 Phase III Clinical Trial (“AMP-516 Trial”) in support of its New Drug Application (“NDA”) for Ampligen^® (Poly I : Poly C₁₂U). If found sufficient to support approval of the drug, these new analyses will be in lieu of an additional confirmatory Phase III study called for in the Agency’s November 25, 2009, Complete Response Letter (“CRL”). The FDA has advised that whether the new analyses provide adequate evidence of Ampligen^®‘s efficacy in treating Chronic Fatigue Syndrome (“CFS”) will ultimately be a review issue.

In its CRL, the FDA recommended at least one additional clinical study of Ampligen^® in CFS patients, including at least 300 patients on dose regimens intended for marketing. In November 2010, Hemispherx announced the publication of new analyses of data from the AMP-516 Trial showing that patients on Ampligen^® reduced their use of concomitant medications compared to patients receiving placebo. In particular, Ampligen^® patients reduced their use of medications which may prolong the QT interval. Prolongation of the QT interval is a known risk factor for sudden cardiac death and arrhythmias. A greater portion of the placebo patients were found to have a significant prolongation of the QT interval compared to patients who had received Ampligen®, thereby creating a cardiac risk situation in the CFS patients. Cardiac death is one of three major causes of premature death in CFS, which affects predominantly women in their 40s. The article can be found at http://jrnlappliedresearch.com/articles/Vol10Iss3/Vol10%20Iss3Stouch.pdf. At present, no drug has received FDA approval to treat this chronic, seriously debilitating disease.

In March, 2012, a new peer reviewed analysis of data from the AMP-516 Trial was published showing that the proportions of Ampligen^® patients with exercise improvements of at least 25% and at least 50% were, respectively, 1.7 and 1.9-fold greater than those patients on placebo. A continuous responder analysis, which examined response improvements from 25% to 50% in 5% increments, showed a greater improvement in exercise tolerance for patients receiving Ampligen^® versus placebo at every 5% increment above 25%. The article can be found at http://dx.plos.org/10.1371/journal.pone.0031334.

On June 8, 2012, the Company and its consultants met with the FDA to discuss certain aspects of the CRL relating to its NDA for Ampligen^® for the treatment of severely debilitated patients with CFS.  At this time, the Company believes the key points from the meeting to be undertaken by the Company in conjunction with its complete response include the following:

• The FDA agreed to accept, for review, in Hemispherx’s complete response new analyses of data from the AMP-516 Trial. Whether these data provide adequate evidence of efficacy will ultimately be a review issue, and there can be no assurance the FDA will conclude the data are adequate to support approval of the Ampligen^® NDA.
• As the product is a new molecular entity, the FDA anticipates that the data submitted in the NDA would be presented at a public FDA Advisory Committee meeting.
• The FDA requires that the Company’s complete response include all information necessary for review at the time of filing and that it address all deficiencies identified in the CRL.
• Hemispherx’s New Brunswick manufacturing facility would be expected to be ready for GMP pre-approval inspection at the time of the complete response.
• Hemispherx will include in the complete response a request for postponement of rodent carcinogenicity study requirements and a justification for this request.

Hemispherx plans to submit the complete response in the 3^rd quarter 2012. The FDA has advised that, once submitted, the complete response will be on a six month review cycle at the FDA. The FDA’s agreement to review the complete response does not commit the Agency to approve the Ampligen^® NDA. Further, although the proposed New Brunswick manufacturing facility already has received a Biologics License from the FDA for its commercial product, Alferon N Injection^®, no guarantee can be made at this time that the facility will necessarily pass a pre-approval inspection for Ampligen^® manufacture, which is conducted in a separately dedicated area within the overall New Brunswick manufacturing complex.

As a result of the meeting, Hemispherx has accelerated its preparedness for FDA pre-approval inspections by hiring additional staff, consultants, and various independent contractors.

DISCLOSURE NOTICE: The information in this press release includes certain “forward-looking” statements (explained below), including statements about the remaining steps to potentially gain FDA approval of the Ampligen^® NDA for the treatment of Chronic Fatigue Syndrome. The final results of these and other ongoing activities could vary materially from Hemispherx’s expectations and could adversely affect the chances for approval of the Ampligen^® NDA. These activities and the ultimate outcomes are subject to a variety of risks and uncertainties, including but not limited to risks that (i) the complete response Hemispherx ultimately submits in support of the Ampligen^® NDA may not be accepted by the FDA or such acceptance may be delayed; (ii) the FDA may ask for additional data, information or studies to be completed or provided prior to approval; (iii) the FDA may require additional work related to the commercial manufacturing process to be completed prior to approval or may, in the course of the inspection of manufacturing facilities, identify issues to be resolved; and (iv) the FDA may determine that the complete response ultimately submitted by Hemispherx is not “complete,” potentially requiring the Company to conduct additional activities before it can re-file, if at all, the complete response. Any failure to satisfy the FDA’s requirements could significantly delay, or preclude outright, approval of the Ampligen^® NDA.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders.  Hemispherx’s flagship products include Alferon N Injection^® (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen^® and Alferon^® LDO.  Because both Ampligen^® and Alferon LDO^® are experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. Ampligen is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system including Chronic Fatigue Syndrome.  Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases.  Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection).  The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.  For more information please visit www.hemispherx.net.

Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “believes,” “plans,” “anticipates,” and similar expressions are intended to identify forward-looking statements. These statements are based on the company’s current beliefs and expectations and represent the Company’s judgment as of the date of this release. The inclusion of forward-looking statements should not be regarded as a representation by Hemispherx that any of its plans will be achieved. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond Hemispherx’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Examples of such risks and uncertainties include those set forth in the Disclosure Notice, above, as well as the risks described in Hemispherx’s filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Hemispherx undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise revise or update this release to reflect events or circumstances after the date hereof.

CONTACT: Company/Investor Contact:
         Dianne Will
         Hemispherx Biopharma, Inc.
         518-398-6222
         ir@hemispherx.net

GeoGlobal (GGR) Announces Sale of Shares in ILDE

CALGARY, ALBERTA — (Marketwire) — 07/11/12 — GeoGlobal Resources Inc. (“GeoGlobal” or the “Company”) (NYSE MKT:GGR)(NYSE Amex:GGR) today announced that it has sold 8,500,000 shares acquired in the Securities Purchase and Exchange Agreement (the “Agreement”) by and between the Company and The Israel Land Development Company – Energy Ltd. (“ILDE”), dated as of November 21, 2011. GeoGlobal sold the shares of ILDE through two Israeli investment houses, on an off market basis, at a 12% discount to market due to the shares being restricted until the end of August 2012. Net proceeds to GeoGlobal from the sale of the shares are approximately US$1.4 million.

“We sold a modest portion of our holding in ILDE purely for working capital purposes and retain a significant holding in ILDE. We continue to believe there is real value in our investment in that organization,” said Paul B. Miller, President and CEO of GeoGlobal. “The proceeds from the sale will be directly applied to meeting our capital commitments in the Myra and Sara Blocks. The drilling of Myra-1 is progressing as planned and we anticipate reaching TD in August as previously reported. This is an exciting time for GGR and its partners in the region and we continue to be excited by the prospects.”

About GeoGlobal

GeoGlobal Resources Inc., headquartered in Calgary, Alberta, Canada, is a U.S. publicly traded oil and gas company, which, through its subsidiaries, is engaged in the pursuit of petroleum and natural gas in high potential exploration targets through exploration and development in India, Israel and Colombia.

Cautionary Statement For Purposes Of The “Safe Harbor” Provisions Of The Private Securities Litigation Reform Act Of 1995

This press release contains statements which constitute forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995, including statements regarding the plans, intentions, beliefs and current expectations of GeoGlobal Resources Inc., its directors, or its officers with respect to the oil and gas exploration, development and drilling activities being conducted and intended to be conducted and the outcome of those activities on the exploration blocks in which the Company has an interest. The company updates forward-looking information related to operations, production and capital spending on a quarterly basis and updates reserves, if any, on an annual basis.

We caution you that various risk factors accompany our forward-looking statements and are described, among other places, under the caption “Risk Factors” in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. These risk factors could cause our operating results, financial condition and ability to fulfill our plans to differ materially from those expressed in any forward-looking statements made in this press release and could adversely affect our financial condition and our ability to pursue our business strategy and plans. If our plans fail to materialize, your investment will be in jeopardy.

An investment in shares of our common stock involves a high degree of risk. Our periodic reports we file with the Securities and Exchange Commission and Canadian provincial authorities may be viewed at http://www.sec.gov and www.sedar.com.

Contacts:
GeoGlobal Resources Inc.
Paul B. Miller
President and CEO
+1 403 777-9250
info@geoglobal.com
www.geoglobal.com

KM Investor Relations Ltd.
Moran Meir-Beres
+011 972-3-5167620
moran@km-ir.co.il
www.km-ir.co.il

The Equicom Group
Dave Feick
Managing Director
Western Canada
+1 403 218-2839

Complete Genomics (GNOM) Announces Standard-Setting Clinical-Grade Genome Technology

Long Fragment Read Technology Described in Nature Paper Provides Much Higher Accuracy Sequencing

MOUNTAIN VIEW, Calif., July 11, 2012 (GLOBE NEWSWIRE) — Complete Genomics, Inc. (Nasdaq:GNOM) today announced that its Long Fragment Read (LFR) technology for whole genome sequencing dramatically improves accuracy, enables fully-phased genomes, and significantly reduces the amount of DNA required for testing. Complete’s LFR technology should accelerate the use of whole genome sequencing by physicians to diagnose and treat their patients.

“We expect the introduction of this technological breakthrough to accelerate the move of whole genome sequencing into patient care, which in turn will begin to change the face of medicine,” said Dr. Clifford Reid, Complete Genomics’ chairman, president and CEO.

“The Nature paper by Peters et al. describes how our LFR technology uses ‘barcoded’ DNA to generate whole genome sequencing with approximately one error in 10 million base pairs, or just 600 errors in an entire human genome,” said Dr. Rade Drmanac, the company’s chief scientific officer and inventor of the LFR technology. “This represents a 10-fold increase in accuracy for Complete and is unmatched by any high-sensitivity method currently available.”

Until now, determining whether two disease-associated variants were on the same or different parental chromosomes was either impossible or required expensive, low-throughput technologies — an approach often infeasible in a clinical environment. Complete’s new LFR technology not only enables an accurate identification of mutations, but includes phasing that shows which mutations are in fact together on the same parental chromosome. Through phasing, a physician can determine whether a patient with two pathogenic variants in a gene including its regulatory regions is affected or merely a carrier of the trait. In addition, Complete’s LFR technology provides, for the first time, accurate whole-genome sequencing from as few as 10 to 20 cells (only 100 picograms of DNA), making it an ideal choice for small sample clinical sequencing applications including circulating tumor cells, fine needle aspirations, and pre-implantation genetic diagnostics.

“In the not-too-distant future, failure to use phasing when providing genomic diagnoses in patient care will be seen as unacceptably inaccurate,” said Dr. George Church, professor of genetics at Harvard Medical School and director of PersonalGenomes.org. “I also suspect that LFR will reveal surprising things we didn’t know were missing because we didn’t have a tool to see them.”

The U.S. Patent and Trademark Office has already issued Complete Genomics two separate patents on LFR technology, and additional patent applications, including miniaturization using nanodrops, are pending. Complete Genomics plans to incorporate the new technology into its sequencing offerings in early 2013.

About Complete Genomics

Through its pioneering sequencing-as-a-service model, Complete Genomics provides the most accurate whole human genomes generally available today. The ease of use and power of Complete’s advanced informatics and analysis systems provide genomic information needed to better understand the prevention, diagnosis, and treatment of diseases. Additional information can be found at http://www.completegenomics.com.

The Complete Genomics logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8216

Forward-Looking Statement

Certain statements in this press release, including the incorporation of LFR technology into genomic sequencing and the potential future impact of LFR technology on medical care, are forward-looking statements that are subject to risks and uncertainties. These forward-looking statements are based on management’s current expectations, and actual results may differ materially from our expectations. The following factors, without limitation, could cause actual results to differ materially from those in our forward-looking statements: the timing of the company’s incorporation of LFR technology into its sequencing offerings and the pace of acceptance of human genome sequencing into patient care. More information on risk factors that could affect our results can be found in our Annual Report on Form 10-K filed with the SEC on March 9, 2012, and our Quarterly Report on Form 10-Q filed with the SEC on May 9, 2012, including those risks listed in those filings under the heading “Risk Factors.” We disclaim any obligation to update information contained in our forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: For more information, contact:

         Waggener Edstrom Worldwide Healthcare
         Lisa Osborne
         Account Director
         (202) 261-7806
         lisao@waggeneredstrom.com

Ocean Power Tech (OPTT) and Lockheed Martin to Develop Wave-Energy Project

Duma (DUMA) Energy Enters Negotiations for African Concession

HOUSTON, July 11, 2012 (GLOBE NEWSWIRE) — Duma Energy Corp. (OTCBB:DUMA) (the “Company”) is pleased to announce that it has entered into the final stage of negotiations regarding the proposed acquisition by the Company of a private corporation with a significant interest in an African concession totaling approximately 6 million acres (25,000 square km) (the “Proposed Acquisition”). The Company is seeking to expand beyond its current U.S. operations and acquire highly prospective opportunities in emerging exploration regions.

“Our success in the last two years has put us in a strong position for growth. We believe it is the right time to be aggressive and continue to pursue our stated goal of seeking projects that offer huge potential returns. There are great opportunities out there,” said Jeremy G. Driver, President and Chief Executive Officer of Duma Energy Corp.

Any such Proposed Acquisition will be subject to the execution of definitive acquisition documentation together with the satisfaction of certain conditions precedent which would be standard in acquisitions of this type.

About Duma Energy Corp.

Duma Energy Corp. is an aggressive growth company actively producing oil and gas in the continental United States, both on and offshore. Duma Energy will continue increasing revenue, cash flow, and reserves to fund its aggressive growth through acquisition and participation in projects with the potential of providing exponential returns for shareholders. Further information can be found on the Company’s website at www.duma.com.

Forward-looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which contain words such as “expect,” “believe” or “plan,” by their nature address matters that are, to different degrees, uncertain. These uncertainties may cause actual future events to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.

CONTACT: Investor Relations
         Investor Awareness, Inc.
         Tony Schor or James Foy
         847-945-2222
         www.InvestorAwareness.com

Court Refuses to Dismiss GSI Technology’s (GSIT) Antitrust Lawsuit against Cypress Semiconductor

GSI Technology, Inc. (Nasdaq:GSIT) announced today that on Friday, July 6, the United States District Court for the Northern District of California in San Jose issued a decision upholding the sufficiency of the antitrust claims asserted by GSI in its Complaint against Cypress Semiconductor Corporation. The Complaint, filed on July 22, 2011, charges Cypress with conducting an unlawful combination and conspiracy, by and through the QDR Consortium, to exclude GSI and other competitors from the market for high-performance static random access memory (SRAM) devices known as fast synchronous Quad Data Rate (or QDR) SRAMs and Double Data Rate (or DDR) SRAMs.

Cypress had moved to dismiss the Complaint arguing that the claims asserted by GSI failed to state a claim under federal or state antitrust laws. In its decision, the Court rejected virtually all of Cypress’ arguments. The Court held that GSI’s Complaint adequately alleges that the anti-competitive, collusive and conspiratorial conduct of Cypress and certain co-conspirators violates Section 1 of the Sherman Act and also constitutes unlawful restraints of trade and unfair competition under applicable provisions of California law. The Complaint seeks treble damages, in an amount to be determined at trial, a preliminary and permanent injunction prohibiting the continuation of the unfair and illegal business practices and recovery of GSI’s attorneys’ fees and costs. The decision in GSI’s favor will allow GSI to pursue pre-trial discovery on all of the claims alleged.

Lee-Lean Shu, GSI’s President and CEO, noted, “We are, of course, pleased with the Court’s ruling. We are confident that the claims we asserted in the Complaint regarding Cypress’ anticompetitive conduct will be proven at trial and will result in a victory, not only for GSI, but also for the QDR SRAM and DDR SRAM market.”

GSI’s lead trial lawyer in the case, Arthur Shartsis of Shartsis Friese, responded to the decision stating: “The Court’s sweeping decision is an important validation of the public standard setting process in high-tech industries. GSI believes that competitors may not privately conspire to set standards in a way that harms open competition.”

On a related matter, Mr. Shu noted that, “as previously announced, we expect to receive the initial determination of the administrative law judge in the pending International Trade Commission proceeding, also involving Cypress, in late July. We continue to believe that the evidence presented in that proceeding clearly supported our position that GSI has infringed no valid Cypress patents.”

About GSI Technology

Founded in 1995, GSI Technology, Inc. is a leading provider of high performance static random access memory, or SRAM, products primarily incorporated in networking and telecommunications equipment. Headquartered in Sunnyvale, California GSI Technology is ISO 9001 certified and has worldwide factory and sales locations. For more information, please visit www.gsitechnology.com.

Gevo (GEVO) and Beta Renewables Sign Cellulosic Isobutanol Development Agreement

Gevo, Inc. (NASDAQ: GEVO), a leading renewable chemicals and next-generation biofuels company, signed a Joint Development Agreement (JDA) with Beta Renewables, a joint venture between Chemtex and TPG, to develop an integrated process for the production of bio-based isobutanol from cellulosic, non-food biomass.

The project would integrate Beta’s PROESA^TM technology and Gevo’s GIFT^® and ATJ technologies, with anticipated production plants to be located where cellulosic feedstocks such as switchgrass, miscanthus, agriculture residues and other biomass will be readily available. The agreement also anticipates commercialization of the technology upon project success, which could enable renewably sourced, competitively priced jet fuel as well as other chemicals and fuels made from isobutanol.

“Gevo has always said that we are feedstock agnostic and, when the technology and feedstock supply chain are ready, we would use our isobutanol process with cellulosic feedstocks. This allows us to access a larger carbohydrate pool as feedstock for isobutanol production, which help keep costs down and enables production facilities in regions of the world rich in biomass resources,” said Gevo COO and President Chris Ryan in a presentation at the U.S. Department of Energy’s BIOMASS 2012 conference. “With the success of our Luverne, Minn. plant startup and Beta Renewables’ cellulosic sugar technology, we’re ready to position Gevo to be on the forefront of cellulosic isobutanol and isobutanol derivatives, such as jet fuel, through the integration of the companies’ respective technology platforms. Beta Renewables is a leader in cellulosic conversion technology and we look forward to a range of collaborations, including partnering with Beta to meet the requirements of the U.S. government’s Defense Production Act Title III project.”

“This is the latest example of Beta Renewables’ PROESA technology enabling lower-cost delivery of bio products – whether cellulosic ethanol from our first-in-the-world, commercial-scale plant in Crescentino, or from GraalBio’s multiple plants; from jet fuel produced in partnership with Gevo or from other bio-based chemicals. Gevo is a leader in the fermentation of sugar into isobutanol and a great partner for this effort,” said Dario Giordano, Chief Technology Officer of Beta Renewables and M&G Corporate Director.

The companies are evaluating future opportunities to partner on other U.S. and international projects with a long-term goal of developing a licensable package for future interested third parties.

Beta Renewables is currently building a 60,000 metric ton (approximately 20 million gallon) per year bio-refinery in Crescentino, Italy that will produce cellulosic ethanol using its PROESA™ process as well as ‘green’ electricity. Construction has begun and plant startup is targeted for the end of 2012.

About Gevo

Gevo is converting existing ethanol plants into biorefineries to make renewable building block products for the chemical and fuel industries. The Company plans to convert renewable raw materials into isobutanol and renewable hydrocarbons that can be directly integrated on a “drop in” basis into existing chemical and fuel products to deliver environmental and economic benefits. Gevo is committed to a sustainable biobased economy that meets society’s needs for plentiful food and clean air and water. For more information, visit www.gevo.com

About Beta Renewables

Beta Renewables is the leader in making non-food cellulosic biomass practical and cost-competitive for the production of advanced biofuels and biochemicals. Beta Renewables is a unique $350 million (€250M) joint venture formed from the Chemtex division of Gruppo Mossi & Ghisolfi and TPG. The company benefits from over 60 years of success in process development and commercializing hundreds of plants worldwide. Beta Renewables has invested over $200 million (€140M) in the development of the PROESA™ process. The company is currently building the world’s first commercial-scale cellulosic ethanol facility in Crescentino, Italy, expected to start operations by the end of 2012.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements that are not purely statements of historical fact, and can sometimes be identified by our use of terms such as “intend,” “expect,” “plan,” “estimate,” “future,” “strive” and similar words. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and the company undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although the company believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2011, as amended, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Gevo.

NeoStem (NBS) to Present at the Seventh Annual JMP Securities Healthcare Conference

NEW YORK, July 10, 2012 (GLOBE NEWSWIRE) — NeoStem, Inc. (NYSE MKT:NBS) (“NeoStem” or the “Company”), a cell therapy company, today announced that its CEO will present at the Seventh Annual JMP Securities Healthcare Conference on July 12, 2012.

The presentation will be webcast live and available to view at the following web address: http://wsw.com/webcast/jmp18/nbs/. The webcast will be archived for 90 days following the live presentation.

The Seventh Annual JMP Securities Healthcare Conference

• Date: July 12, 2012, 2:30 PM EDT
• Venue: The Peninsula, New York, NY
• Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem

About NeoStem, Inc.

NeoStem, Inc. (“we,” “NeoStem” or the “Company”) continues to develop and build on its core capabilities in cell therapy to capitalize on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. Our January 2011 acquisition of Progenitor Cell Therapy, LLC (“PCT”) provides NeoStem with a foundation in both manufacturing and regulatory affairs expertise. We believe this expertise, coupled with our existing research capabilities and collaborations, will allow us to achieve our mission of becoming a premier cell therapy company. Our PCT subsidiary’s manufacturing base is one of the few current Good Manufacturing Practices (“cGMP”) facilities available for contracting in the burgeoning cell therapy industry. Amorcyte, LLC (“Amorcyte”), which we acquired in October 2011, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte’s lead compound, AMR-001, represents NeoStem’s most clinically advanced therapeutic and Amorcyte is enrolling patients for a Phase 2 trial to investigate AMR-001’s efficacy in preserving heart function after a heart attack. We also expect to begin a Phase 1 clinical trial by 2012/2013 to investigate AMR-001’s utility in arresting the progression of congestive heart failure and the associated comorbidities of that disease. Athelos Corporation (“Athelos”), which is approximately 80%-owned by our subsidiary, PCT, is engaged in collaboration with Becton-Dickinson that is exploring the earlier stage clinical development of a T-cell therapy for autoimmune conditions. In addition, our pre-clinical assets include our VSEL^TM Technology platform as well as our MSC (mesenchymal stem cells) product candidate for regenerative medicine.

For more information on NeoStem, please visit www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, including with respect to the Company’s successful development of cell therapeutics, as well as the future of the cell therapeutics industry. The Company’s actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company’s periodic filings with the Securities and Exchange Commission. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Trout Group
         Gitanjali Jain Ogawa, Vice President
         Phone: +1-646-378-2949
         Email: gogawa@troutgroup.com

         NeoStem, Inc.
         Robin Smith, CEO
         Phone: +1-212-584-4174
         Email: rsmith@neostem.com

Origin Agritech (SEED) Provides Update on Corn Seed R&D Programs

Origin Agritech Limited (NASDAQ: SEED) (“Origin” or the “Company”), a technology-focused supplier of hybrid and genetically modified crop seeds in China, today provided update on its Genetically Modified (“GM”) corn seed pipeline and hybrid corn seed development program.

GM Corn Seed Pipeline

Genetically modified seed products in China must initially undergo a five-stage approval process consisting of Phase 1 – Laboratory Research, Phase 2 – Intermediate Test, Phase 3 – Environment Release Test, Phase 4 – Production Test, leading to the receipt of the Bio-Safety Certificate from Ministry of Agriculture (“MOA”) in Phase 5. Currently, only domestic seed producers such as Origin Agritech are allowed to proceed through all five phases, while international companies are restricted to Phase 1 only and forbidden to proceed to Phases 2 through Phase 5.

Origin’s genetically modified phytase corn was the first GM corn seed which passed all five phases of the GM approval process and received notification of Bio-Safety Certificate. Origin has further incorporated phytase traits into two of its best-selling commercial corn hybrids. Commercialization of these two corn hybrids is pending approval from the Chinese government. Two additional corn hybrids with GM phytase traits are undergoing variety production test.

Phytase is an essential element for the growth and development of all animals by increasing phosphorous absorption. Phytase transgenic corn inputs the phytase trait directly into corn, thus reducing costs for animal feed producers by eliminating the need to mix phytase and corn ingredients together. Origin’s GM phytase-producing corn is expected to reduce the need for inorganic phosphate supplements as animals will directly absorb more phosphate from their feed, reducing animal feed’s high cost.

In addition to GM phytase corn, the Company has been conducting research on other GM traits including herbicide tolerance, insect resistance, nitrogen efficiency, and drought stress tolerance traits in crop seeds.

Along with this press release, a supplementary slide showing Origin’s GM corn seed pipeline has been filed with the Securities and Exchange Commission (“SEC”).

The following is a summary of key developments for Origin’s GM corn seeds since 2011:

• Phytase: Two commercial hybrids with phytase traits have completed the variety production test and are pending the variety approval from the Chinese government. Two additional hybrid varieties with phytase traits are currently under variety production test;
• Glyphosate Tolerance: One GM glyphosate tolerance event (the unique DNA recombination event that took place in one plant cell) passed Phase 3 – Environment Release Test in 2011 and has received MOA’s approval to begin Phase 4 – Production Test. Two more glyphosate tolerance events are being submitted for Phase 3 – Environment Release Test. In addition, more than one thousand events are undergoing Phase 1 – Laboratory Research;
• Bacillus Thuringiensis (Bt): Two insect tolerant events are going through Phase 2 – Intermediate Test. Over two hundred events are undergoing Phase 1 – Laboratory Research;
• Glyphosate + Bacillus Thuringiensis (Bt): As a result of recent successes in Phase 1 – Laboratory Research, six events of the Company’s glyphosate and insect tolerant traits have advanced into Phase 2 – Intermediate Test. More than 4,500 events of the stacked traits (inserting more than one gene in a seed via biotechnology) are being screened in Phase 1 – Laboratory Research.

Hybrid Corn Seed Development Program

In addition to GM crop seeds, Origin has a large R&D program developing conventional hybrid crop seeds. In China, new hybrid seed variety needs to go through an official approval process prior to sales. This approval process typically involves three to four years of registration trials and normally proceeds according to the following sequential steps:

Pre-Registration –> Registration Trial 1 –> Registration Trial 2 –> Field Demo –> Approval

Each step leading up to Approval takes approximately one year unless it needs to be repeated. In some localities Registration Trial 2 and Field Demo are treated as one and the same step.

Along with this press release, a supplementary slide showing Origin’s progress in hybrid corn registration trials and approval from 2009 to 2012 has been filed with the SEC.

In 2012, a total of 64 hybrids were under various stages of registration process: among the 64 hybrids, 33 are at Pre-Registration stage; 18 at Registration Trial 1 stage; 5 at Registration Trial 2 stage; 5 at Field Demo stage; and 3 at Registration Trial 2 + Field Demo stage. As the result of multi-year trials, 3 corn hybrids have been approved in 2012.

Dr. Gengchen Han, Chairman and Chief Executive Officer of Origin Agritech, commented, “During recent years, we have established a leading plant genetic technology platform resulting in one of China’s largest portfolios in GM corn seeds. We are well positioned to capitalize on the advent of genetically modified seed opportunities in China. In addition to our proven GM technology and robust pipeline, our solid operational foundation with wide-reaching sales and technical support, growing in-house germplasm library, and advanced processing and production would help us compete effectively in the market. Our goal is to continue utilizing modern biotechnology to create high-quality GM and hybrid seed products and provide result-oriented solutions to farmers.”

About Origin

Founded in 1997 and headquartered in Zhong-Guan-Cun (ZGC) Life Science Park in Beijing, Origin Agritech Limited (NASDAQ GS: SEED) is China’s leading agricultural biotechnology company, specializing in crop seed breeding and genetic improvement, seed production, processing, distribution, and related technical services. Leading the development of Genetically Modified (GM) technology, Origin Agritech’s phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China’s Ministry of Agriculture. Over the years, Origin has established a robust GM seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits. Staffed by approximately 800 employees, Origin operates 13 marketing centers, 8 production and processing centers and 9 breeding stations nationwide with sales centers located in key crop-planting regions. The Company also operates one winter nursery in Hainan province. Product lines are vertically integrated for corn, rice and canola seeds. For further information, please log on to the Company’s website at: www.originseed.com.cn

Forward Looking Statement

This release contains forward-looking statements. All forward-looking statements included in this release are based on information available to us on the date hereof. These statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results to differ materially from those implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “targets,” “goals,” “projects,” “continue,” or variations of such words, similar expressions, or the negative of these terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Neither we nor any other person can assume responsibility for the accuracy and completeness of forward-looking statements. Important factors that may cause actual results to differ from expectations include, but are not limited to, those risk factors discussed in Origin’s filings with the SEC including its annual report on Form 20-F. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

UBPS (UBPSW) to Acquire and Consolidate Three Business Payment Companies

Universal Business Payment Solutions Acquisition Corporation (“UBPS” or the “Company”) (NASDAQ: Common Stock:“UBPS”, Units:“UBPSU”, Warrants:“UBPSW”), a special purpose acquisition company, today announced that it has entered into definitive agreements to acquire three profitable and growing companies to facilitate its strategy of providing end-to-end transaction processing services to small businesses:

• Electronic Merchant Systems (“EMS”), a major credit and debit card sales organization;
• Jet Pay LLC (“JetPay”),atop-15 U. S. credit and debit card processor according to Nilson; and
• A D Computer Corporation (“AD Computer”) and Payroll Tax Filing Services, Inc. (“Payroll Tax Filing”), related payroll processing and tax filing companies.

Mr. Bipin Shah, Chairman and CEO of UBPS, stated, “When we formed UBPS the aim was to follow through on a simple concept ~ small business owners should be able to receive all of their business processing solutions in one place. After a thorough diligence and evaluation process, we feel we have succeeded in offering such solutions with the combination of UBPS and these three profitable and rapidly-growing companies. We believe this ‘all encompassing’ business processing model offers a unique solution not currently available to small business customers. We also worked very diligently at creating a structure that was both internally friendly for these three companies while also providing current and potential investors a valuation greater than that available through investment in other publicly-traded companies in the market.”

Details of Transaction

UBPS will acquire the three companies in a transaction valued at approximately $179 million, of which $104 million will be paid in cash, $38 million in newly issued UBPS common stock, and the balance as future payments in cash and UBPS stock (with $25 million of such future payments contingent on the achievement of certain targets). The cash portion of the consideration will be funded by a combination of a $60 million credit facility and UBPS cash held in trust.

The business combination is subject to approval by the Company’s stockholders, as well as regulatory approval and other customary closing conditions. Assuming these conditions are met, the business combination is expected to close early in the fourth quarter of this year.

Financial Results

On a pro-forma basis for calendar year ended December 31, 2011, the combined entities generated over $70 million in revenues and $17 million in EBITDA, without giving effect to immediately identifiable synergies which UBPS estimates to be in excess of $3.5 million. UBPS expects on a pro-forma basis that the combined company will have $78.9 million in revenue and $20.8 million EBITDA in CY 2012 based solely on the benefits of scale and current organic growth.

Compelling Transaction Valuation Compared to Public Peers

• 8.3x 2012E EBITDA and 6.1x 2013E EBITDA versus publicly-traded peers of 9.9x and 8.9x*
• 12.7x 2012E net income and 8.2x 2013E net income versus peers of 22.1x and 17.9x*

* Based upon UBPS price per common share of $6.08 (current total in trust) \ All data as of June 25, 2012 – Source Capital IQ

Background on Acquisition Businesses

• EMS – Since 1987, EMS has grown to become a leading provider of merchant processing services and electronic transactions. Based in Cleveland, Ohio, the company operates in over 100 U.S. cities serving over 16,000 customers across the country. EMS provides high-quality payment processing services and support to traditional retail merchants. EMS processes and safeguards many types of electronic payment transactions including all major credit cards, debit cards, EBT, stored-value, and electronic check services.
• JetPay is a front and back-end credit and debit card and check processor located in Carrollton, TX, offering a wide array of business processing services and features, combining real-time credit and debit card processing, online payment capabilities, and merchant account services into one solution. With more than two decades of experience, JetPay is a Top 15 payment processing company in volume in the U.S. according to Nilson. The company offers processing services to banks, sales organizations, merchants, and for a number of large e-commerce sites on the web today.
• Since 1971, AD Computer and its related company, Payroll Tax Filing are headquartered near Allentown, PA and have provided comprehensive payroll and payroll tax filing services to businesses of all types and sizes throughout the United States. AD Computer’s payroll system is designed with optimum flexibility to accommodate payrolls of all sizes – from small family businesses to large corporations with up to 10,000 employees. The company has historically focused on local markets in the Lehigh Valley, Pennsylvania region, but has created an adaptable payroll processing infrastructure with capacity to expand into other markets under UBPS.

Innovative Combination to Fill Growing Industry Need

The Company feels that its addressable market is primarily U.S. small business, which according to the US Economic Census currently comprises approximately 30% of the Country’s GDP ($4 trillion) and almost half of the national workforce. Currently, the small business owner primarily requires five distinct payment transaction services: payroll processing and related employee services; debit and credit card processing / accounts receivable processing and billing; accounts payable and procurement; funding related to debit and credit card processing receipts; and stored value card products (PayCards, gift cards, others) for employees. The industry has undergone a period of consolidation, with several companies seeking the necessary scale to compete.

Mr. Shah continued, “The market for payroll processing, card processing and funding is still relatively fragmented, with the majority of small businesses utilizing separate resources for each. We feel that by combining these three companies, we can address this market by providing a complete turnkey business processing solution for customers and do it efficiently. For example, whereas a restaurant may have previously gone to separate companies to get its employee a debit card, process their payroll, and access daily working capital; they can now receive all of those services from UBPS as a one-stop shop. These three companies have a strong and successful history, largely created by the talent of their employees and management. We are looking forward to maximizing the scale of the combined entity, and believe that we have truly created a platform to begin providing a processing structure that is currently not available on the market.”

Upon closing, UBPS expects to serve more than 23,000 small business customers through approximately 400 employees, with significant capacity for expansion. In addition to a strong recurring revenue stream, the combination creates a platform company with the scale to support considerably more small business customers. UBPS believes that while it will be cautious to ensure that the three companies are merged with the least disruption to its customers and employees, management expects that the integration should be completed within 12 months. The Company’s corporate headquarters will continue to be based in Chester County, Pennsylvania.

Industry Leading Management

The UBPS management team will be led by Bipin C. Shah, a renowned innovator in the payments processing industry and referred to as the “founder of debit.” Mr. Shah, who will remain Chairman and CEO of the combined company, was instrumental in developing and expanding the first branded multi-bank ATM Network, known as “MAC” for Money Access Card and Money Access Centers. While serving as Vice Chairman and Chief Operating Officer at CoreStates Financial Corporation, and a Board Member of Visa International, Mr. Shah created the first point-of-sale debit card, an electronic universal debit and credit authorization and capture system, “pay-at-the-pump,” and “cash back” at point-of-sale (POS).

The Company will retain senior members of management of the three platform companies after the close of the transaction:

• Dan Neistadt, President of EMS, and formerly EVP at KeyBank and on MasterCard’s Debit Access Committees and former President of the ETA.
• Trent Voigt, President of JetPay, former EVP of Vectrix, and director at National Business Systems.
• Nick Antich, President of A D Computer, the company he founded in 1971.

The UBPS management team is rounded out by Peter Davidson, CAO, formerly EVP of Genpass, and earlier senior management positions with CoreStates Financial, HSBC and Speer & Associates. UPBS’s management team has a strong track record of achieving returns for its investors and shareholders: combined, Gensar, Genpass and MAC/POS returned an average IRR of 62%.

Concluding Comments From Member of the UBPS Board

Arthur F. Ryan, current UBPS board member and former CEO, Prudential Financial Inc., President and COO of Chase Manhattan Bank, and member of the Board of Visa International, stated, “When I joined the Board of UBPS, our entire goal was to seek and find a solution to the growing needs of the small business owner. I think that Bipin and his team have created a thorough and detailed strategy to leverage three companies as a platform to meet all payment-related needs of these businesses. Having worked with Bipin closely for over 25 years, I feel there is no industry peer that has the experience and results in bringing new products to market, driving down transaction processing costs, and in generating additional processing volume via organic growth and acquisitions. We are enthusiastic to begin integrating these companies and creating a bundled service for our current customer base and large potential market of small business owners.”

Additional Investor Information

UBPS intends to file an investor presentation on Form 8-K with the U.S. Securities and Exchange Commission (SEC) in conjunction with this press release.

The Company will also mail a definitive proxy statement and other relevant documents to its stockholders. UBPS management encourages all current and potential investors and other interested persons to read, when available, the preliminary proxy statement, and amendments thereto, and definitive proxy statement in connection with the Company’s solicitation of proxies for the special meeting to be held to approve the business combination because these proxy statements will contain important information about the Company and the proposed business combination. The definitive proxy statement will be mailed to stockholders of the Company as of the record date to be established for voting on the business combination. Stockholders will also be able to obtain a copy of the preliminary and definitive proxy statement, without charge, once available, at the SEC’s Internet site at http://www.sec.gov.

About UBPS

Universal Business Payment Solutions Acquisition Corporation is a blank check company formed for the purpose of acquiring one or more operating businesses in the payments and payroll processing industries as a platform for further roll-up acquisition opportunities. The Company raised net proceeds of approximately $72 million through its initial public offering in May 2011 led by EarlyBirdCapital, Inc. Please visit www.ubpsac.com for more information.

Participants in the Business Combination

The Company and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of the Company in connection with the proposed business combination. Information regarding the officers and directors of the Company is available in the Company’s annual report on Form 10-K for the year ended December 31, 2011, which has been filed with the SEC. Additional information regarding the interests of such potential participants will be included in the definitive proxy statement/prospectus for the proposed business combination and the other relevant documents filed with the SEC.

Note Regarding Financial Information

Certain financial information and data of EMS, JetPay, and AD Computer contained in this press release is derived from unaudited financial statements and data and may not conform to Regulation S-X. Accordingly, such information and data may be adjusted and presented differently in the proxy materials to be mailed to the Company’s security holders.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. UBPS’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, UBPS’s expectations with respect to future performance and anticipated financial impacts of the proposed transaction, the satisfaction of the closing conditions to the proposed transaction, and the timing of the completion of the proposed transaction. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside UBPS’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to, those described under the heading “Risk Factors” in UBPS’s final prospectus, dated May 9, 2011. Other factors include the possibility that the transactions contemplated by a potential transaction agreement do not close, including due to the failure of certain closing conditions.

UBPS cautions that the foregoing list of factors is not exclusive. Additional information concerning these and other risk factors is contained in UBPS’s most recent filings with the Securities and Exchange Commission. All subsequent written and oral forward-looking statements concerning UBPS, a potential transaction agreement, the related transactions, or other matters and attributable to UBPS or any person acting on its behalf, are expressly qualified in their entirety by the cautionary statements above. UBPS cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. UBPS does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Central European Distribution Corp. (CEDC) and Russian Standard Sign Amended Definitive Agreements

– Russian Standard Confirms its Commitment to Strategic Alliance with CEDC – Reconfirms Its Commitment to Purchase Up to $210M of Newly Issued CEDC Senior Notes – Proceeds To Extinguish CEDC 2013 Notes – CEDC Announces Management Changes, Board Addition

Brightstar and iGo, Inc. (IGOI) Announce Global Distribution Agreement

SCOTTSDALE, Ariz., July 9, 2012 (GLOBE NEWSWIRE) — iGo, Inc. (Nasdaq:IGOI) announced today a global distribution agreement with Brightstar Corp., the world’s largest specialized wireless distributor, whereby Brightstar will distribute a line of mobile accessories under iGo’s Adapt Mobile brand.

The first products under the global distribution agreement will ship to Brightstar during the third quarter of 2012.

“Brightstar is the perfect partner to help us increase sales globally into Carrier, Retailer, and Dealer channels,” said Michael D. Heil, President and Chief Executive Officer of iGo, Inc. “With their global reach into more than 50 countries and 80,000 points of sale, Brightstar is becoming a major force in the mobile accessories category.”

About iGo, Inc.

iGo, Inc. offers a full line of innovative accessories for almost every mobile electronic device on the market. Whether a consumer wants to power, protect, listen to, share, cool, hold or connect to their device, iGo has the accessories they need. iGo is also a leader in developing eco-friendly power solutions based on its patented iGo Green® technology, which automatically reduces the wasteful and expensive standby, or “vampire,” power consumed by electronic devices.

iGo’s products are available at www.iGo.com as well as through leading resellers and retailers. For additional information call 480-596-0061, or visit www.igo.com.

iGo is a registered trademark of iGo, Inc. All other trademarks or registered trademarks are the property of their respective owners.

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. The words “believe,” “expect,” “anticipate,” “should,” and other similar statements of our expectation identify forward-looking statements. Forward-looking statements in this press release include the Company’s expectation that the distribution agreement with Brightstar can help increase sales globally into operator, retailer and dealer channels. These forward-looking statements are based largely on management’s expectations and involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks that could cause results to differ materially from those expressed in these forward-looking statements include, among others, our ability to expand and diversify our customer base; increased focus of consumer electronics retailers on their own private label brands; our ability to expand our revenue base and develop new products and product enhancements; fluctuations in our operating results because of: increases in product costs from our suppliers, our suppliers’ ability to perform, the timing of new product and technology introductions and product enhancements relative to our competitors, market acceptance of our products, the size and timing of customer orders, our ability to effectively manage inventory levels, delay or failure to fulfill orders for our products on a timely basis, distribution of or changes in our revenue among distribution partners and retailers, our inability to accurately forecast our contract manufacturing needs, difficulties with new product production implementation or supply chain, product defects and other product quality problems, the degree and rate of growth in our markets and the accompanying demand for our products, our ability to expand our internal and external sales forces and build the required infrastructure to meet anticipated growth, and seasonality of sales; our ability to manage our inventory levels; decreasing sales prices on our products over their sales cycles; our failure to integrate acquired businesses, products and technologies; our reliance on and the risk relating to outsourced manufacturing fulfillment of our products, including potential increases in manufacturing costs; the negative impacts of product returns; design and performance issues with our products; liability claims; our failure to expand or protect our proprietary rights and intellectual property; intellectual property infringement claims against us; our ability to hire and retain qualified personnel; our ability to secure additional financing to meet our future capital needs; increased competition and/or reduced demand in our industry; our failure to comply with domestic and international laws and regulations; economic conditions, political events, war, terrorism, public health issues, natural disasters and similar circumstances; that our common stock could be delisted from the NASDAQ Global Market; volatility in our stock price; concentration of stock ownership among our executive officers and principal stockholders; provisions in our certificate of incorporation, bylaws and Delaware law, as well as our stockholder rights plan, that could make a proposed acquisition of the Company more difficult; and dilution resulting from potential future stock issuances.

Additionally, other factors that could cause actual results to differ materially from those set forth in, contemplated by, or underlying these forward-looking statements are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011 under the heading “Risk Factors.” In light of these risks and uncertainties, the forward-looking statements contained in this press release may not prove to be accurate. The Company undertakes no obligation to publicly update or revise any forward-looking statements, or any facts, events, or circumstances after the date hereof that may bear upon forward-looking statements. Additionally, the Company does not undertake any responsibility to update you on the occurrence of unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements.

CONTACT: Tony Rossi
         Financial Profiles
         310-478-2700 x13
         trossi@finprofiles.com

Securities Lawyers Seek to Improve Shareholder Value at THQ (THQI)

DALLAS, July 9, 2012 /PRNewswire/ — Goldfarb LLP is investigating whether the board of directors of THQ, Inc. (NASDAQ: THQI) violated shareholder protection laws by issuing materially false and misleading statements to investors that artificially inflated the company’s stock price. Concerned THQI investors who held shares before February 3, 2011 are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbllp.com about their rights and remedies.

“The company is accused of issuing false and misleading statements regarding the company’s uDraw GameTablet and its lack of appeal to Microsoft Xbox 360 and Sony PlayStation 3 owners,” securities lawyer Hamilton Lindley said. “Our proposed shareholder lawsuit will seek to ensure that proper controls are placed to correct any improper behavior, and to improve the company’s value for investors.”

Goldfarb LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. THQ, Inc. shareholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at hlindley@goldfarbllp.com or 877-583-2855.

Hamilton Lindley
Goldfarb LLP
2501 N. Harwood, Ste. 1801
Dallas, TX 75201
(877) 583-2855 Toll Free Telephone
(214) 583-2233 Local Phone Number
(214) 583-2234 Fax Number
hlindley@goldfarbllp.com
www.goldfarbllp.com

GlobalWise (GWIV) ECM Software Intellivue™ Named #1 at Prestigious Managed Printer Conference

COLUMBUS, OH — (Marketwire) — 07/09/12 — GlobalWise Investments, Inc. (OTCBB: GWIV) (OTCQB: GWIV) (the “Company”) (www.GlobalWiseInvestments.com) and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, today announce the Company’s Intellivue™ ECM software was named the number one ECM solution at the recent Global Transform 2012 conference by “The Week in Imaging.”

“The Week in Imaging” (www.theweekinimaging.com) is an online, interactive one-stop news and information source that targets anyone who sells imaging solutions, including independent dealers, VARs, sales and service personnel in manufacturer direct branches as well as hardware manufacturers and solutions and service providers. Global Transform 2012 is a managed print service (MPS) industry conference for providers, partners and IT decision makers in the copier and printer industry.

The online article (www.theweekinimaging.com/author/theweek/page/8/) posted by Art Post on the “The Week in Imaging” Web page and titled “Top 7 Solutions at Photizo’s Transform Conference: Intellivue Cost-Per-Page Billing for Document Management Services @ #1” provides a great overview of the Intellivue™ cloud based document management software and how it can create a new revenue model for the copier and printer dealer industry. The number one ranking by such a prestigious industry resource is a great validator of the power of a cloud delivered software from GlobalWise.

“I am very proud of our team and how well received the Intellivue™ software was at the Transform Conference,” commented William J. “BJ” Santiago, CEO of GlobalWise. “We shared a booth with MWA Intelligence, a new GlobalWise Channel Partner recently announced, and to be recognized as the #1 solution at the show by our industry peers at ‘The Week in Imaging’ is a fantastic win. Copier and printer dealers traditionally derive their income from leasing of hardware and charging for every page printed. Scanning and retrieval of documents was done at no cost to the client, but with little functionality. By integrating the Intellivue™ software into the imaging hardware, copier dealers can instantly expand their service portfolio with an additional value-added offering, creating a new revenue stream.”

“The power of this solution is that there is no upfront cost,” author Art Post stated in the recently published article. “I see Intellivue™ as a tremendous value for the SMB customer. For too long the SMB customer has shied away from content management due to the upfront cost, the training, the IT infrastructure and the thought that they would have to dedicate an employee to operate the software. With this SaaS solution, a company can realize an immediate return on investment from the first month Intellivue™ is deployed.”

About GlobalWise Investments, Inc.

GlobalWise Investments, Inc., via its wholly owned subsidiary Intellinetics, Inc., is a Columbus, Ohio based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet or smartphone from anywhere in the world.

For additional information, please visit the Company’s corporate website: www.GlobalWiseInvestments.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

GlobalWise Investments, Inc.
Columbus, Ohio
www.GlobalWiseInvestments.com
614-388-8909
Contact@GlobalWiseInvestments.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975

Shareholders of Exceed Company Ltd. (EDS) Approve All Board Proposals

Silver Bull (SVBL) Files Updated NI43-101 Report for Sierra Mojada Project

TPI (TPI) Provides Further Updates on its GMOL Flagship Product

AVI BioPharma (AVII) to Present Company Overview

BOTHELL, WA — (Marketwire) — 07/06/12 — AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that it is scheduled to present at the Seventh Annual JMP Securities Healthcare Conference in New York, NY on Thursday, July 12, at 1:30 p.m. Eastern Time. Chris Garabedian, AVI’s President and CEO, will be the presenter.

The presentation will be webcast live under the events section of AVI’s website at www.avibio.com and will be archived there following the presentation for 90 days. Please connect to AVI’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About AVI BioPharma
AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, AVI’s technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging its highly differentiated RNA-based technology platform, AVI has built a pipeline of potentially transformative therapeutic agents, including eteplirsen, which is in clinical development for the treatment of Duchenne muscular dystrophy, and multiple drug candidates that are in clinical development for the treatment of infectious disease. For more information, please visit www.avibio.com.

AVI Media and Investor Contact:
Erin Cox
425.354.5140
Email Contact

Cameco and Denison Mines (DNN) on the Upswing as Japan Restarts Two Nuclear Reactors

NEW YORK, NY — (Marketwire) — 07/06/12 — Uranium stocks have been on the upswing recently as Japan has restarted their first nuclear reactor since the Fukushima disaster. The Global X Uranium ETF (URA) — the first ETF to track companies involved in uranium mining — has rebounded over 12 percent in the last month. Five Star Equities examines the outlook for companies in the Uranium Industry and provides equity research on Cameco Corporation (NYSE: CCJ) (TSX: CCO) and Denison Mines Corp. (NYSE: DNN) (TSX: DML).

Access to the full company reports can be found at:

www.FiveStarEquities.com/CCJ

www.FiveStarEquities.com/DNN

Uranium stocks were hit hard in 2011 after a Japanese earthquake and tsunami triggered the worst atomic disaster in 25 years. Following the incident Japan shutdown all 50 of their nuclear reactors, which were responsible for approximately 30 percent of the nation’s electricity. Last week the Japanese government approved to restart the No. 3 and No.4 Ohi units in western Japan.

The “restart of the Japan reactors is likely to be the triggering event to start an upward movement in uranium prices and uranium stocks,” said Steve Laflin, president and CEO of International Isotopes.

Five Star Equities releases regular market updates on the Uranium Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Cameco is one of the world’s largest uranium producers accounting for about 16% of the world’s production from its mines in Canada and the US. Their leading position is backed by about 435 million pounds of proven and probable reserves and extensive resources. Shares of the company have rebounded nearly 18 percent in the last month.

Denison Mines is a uranium exploration and development company with interests in exploration and development projects in Saskatchewan, Zambia and Mongolia. As well, Denison has a 22.5% ownership interest in the McClean Lake uranium mill, located in northern Saskatchewan, which is one of the world’s largest uranium processing facilities.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

www.FiveStarEquities.com/disclaimer

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Five Star Equities

TAT Technologies (TATT) 30%-Owned Subsidiary Secures $3 M Loan From Controlling Stockholder

USA Water Polo Teams Up With Jamba Juice (JMBA) to Fight Childhood Obesity

Jamba Donates Water Polo Balls to Local Schools and Partakes in Water Polo Clinic as Part of U.S. Olympic Water Polo Team Send-Off Event